Light AI Moves Forward on Q3 2025 Wellness Commercialization Plan
Robust usability and User-Interface ("UI") targeted to stimulate adoption
Wellness App demo anticipated within 90 days to support pre-commercialization initiatives
VANCOUVER, BC, April 30, 2025 /CNW/ - Light AI Inc. (" Light AI" or the " Company") (CBOE CA: ALGO) (FSE: 0HC) (OTCQB: OHCFF), a healthcare technology company focused on developing artificial intelligence health diagnostic and wellness solutions, is pleased to announce that it continues to make solid progress towards its Wellness App Q3 2025 commercialization consistent with the Company's prior announcement. Progress is being made on the Wellness App's innovative and intuitive UI design which will provide a seamless and empowering user experience. The Company anticipates showcasing a closed demo of its Wellness App within approximately 90 days to support its pre-commercialization initiatives.
"Our mission is to improve health and wellness by delivering critical information quickly and seamlessly —anytime, anywhere. This is what our Wellness App has been designed to do, and its innovative user interface will deliver an unparalleled and effortless experience, both responsive and empowering, for health and wellness users, which we anticipate resulting in widespread and rapid adoption," said Anthony Schaller, President and Chief Technology Officer of Light AI. "The innovative UI design is an integral component of our commercialization journey positioning Light AI to be the leader in AI with a meaningful presence in front-line healthcare."
Built with experienced oversight and cutting-edge design principles at its core the AI oriented UI offers a seamless, beautifully easy to use navigation experience. Every touchpoint has been designed, reviewed, debated and engineered to make it easy for users to indicate their symptoms of concern, move to a scan, and quickly receive feedback with recommended next steps. Highlights of the Wellness App UI include:
Streamlined Navigation – Clear map of the journey along with simplified menus create an experience easy for users to navigate;
Cross-platform consistency – Whether users are on an IOS or Android device, the experience remains consistent and engaging;
Personalized History and Resources – Users can see prior results and build a baseline of scan results, healthy or in response to reported symptoms; and
Vibrant, Engaging Intuitive Visuals – The vibrant colour palette and typography promote a sense of calm, engagement and positivity.
The innovative and intuitive UI design will roll out to users in a staggered release to allow time for feedback and improvement before full commercial launch anticipated in late 2025.
About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF)
Light AI Inc. is a technology company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images—starting with images of Strep A and anticipated expansion with COVID19 along with other medical conditions —to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective diagnostic tools designed to address critical healthcare challenges.
In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.
ON BEHALF OF THE COMPANY
"George Reznik"
George Reznik
Chief Financial Officer
Telephone: 604-307-6800
Email: [email protected]
For more information, please contact the Company at [email protected] or visit https://light.ai/.
Forward-Looking Information:
This news release includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, including, but not limited to, the Company's research and development and commercialization initiatives, the anticipated inflection of the business, the opportunity related to the commercialization of the Company's software and other statements that contain words such as "believe," "expect," "project," "should," "seek," "anticipate," "will," "intend," "positioned," "risk," "plan," "may," "estimate" or, in each case, their negative and words of similar meaning. By its nature, forward-looking information involves a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. Readers should not place undue reliance on forward-looking information, which is based on the information available as of the date of this news release. For a list of the factors that may affect any of the Company's forward-looking statements, please refer to the Company's annual information form dated April 14, 2025 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under its SEDAR+ profile at www.sedarplus.ca
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a day ago
- Cision Canada
Northern Shield Grants Stock Options
OTTAWA, ON, June 6, 2025 /CNW/ - Northern Shield Resources Inc. (" Northern Shield" or the " Company") (TSXV: NRN) announces that it has granted options to acquire a total of 2,220,000 common shares in the capital of the Company (" Common Shares") to its directors and officers and a further 210,000 to employees and consultants pursuant to its shareholder approved stock option plan (the " Stock Option Plan"). Each option entitles the holder to acquire one Common Share at an exercise price of $0.12 per Common Share until June 6, 2030. Following such grant, Northern Shield now has outstanding under its Stock Option Plan, options to acquire Common Shares equal to just under 8% of Northern Shield's currently outstanding Common Shares. About Northern Shield Resources Northern Shield Resources Inc. is a Canadian-based company known as a leader in generating high-quality exploration targets that views greenfield exploration as an opportunity to find a mineable deposit, near surface, and at relatively low cost. We implement a model driven exploration approach to reduce the risk associated with early-stage projects for ourselves, our shareholders, and the environment. This approach led us to option the Root & Cellar Property from a Newfoundland prospector, who discovered the mineralization, and then its advancement to a large gold-silver-tellurium system. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cision Canada
2 days ago
- Cision Canada
Minsud Announces Option Grant
TORONTO, June 6, 2025 /CNW/ - Minsud Resources Corp. (TSXV: MSR) (" Minsud" or the " Company") is pleased to announce that it has granted options to purchase an aggregate of 600,000 common shares of the Company (the " Stock Options") to certain directors of the Company. The Stock Options are exercisable at a price of $0.60 per share for a period of five years from the date of issuance. As of the date hereof, a total of 16,494,852 common shares of the Company are reserved for issuance under the Company's stock option plan and, after this new grant, 13,876,000 options will be outstanding. About Minsud Resources Corp. Minsud is a mineral exploration company focused on exploring its flagship Chita Valley Cu-Mo-Au-Ag-Pb-Zn Project, in the Province of San Juan, Argentina. The Company's shares are listed on the TSX-V under the trading symbol "MSR", and on the OTCQX under the symbol "MDSQF". Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Minsud Resources Corp.
Cision Canada
2 days ago
- Cision Canada
Graham Rosenberg Proposed Sale of Shares
TORONTO, June 6, 2025 /CNW/ - Graham Rosenberg (the "Selling Shareholder"), the Chief Executive Officer and Chairman of the Board of dentalcorp Holdings Ltd. (the "Company"), announces that he has filed a notice of intention to distribute securities in connection with the his intention to sell, directly or indirectly, up to 477,700 subordinate voting shares of the Company ("SVS"), 450,000 of which will be issued upon the conversion of multiple voting shares of the Company ("MVS" and together with the SVS, the "Shares") in accordance with their terms (the "Sale"). After the Sale, Mr. Rosenberg will, directly or indirectly, retain over 95% of his securities in the Company, including 100% of the Company's issued and outstanding MVS. Mr. Rosenberg plans to use the proceeds from the Sale for tax, financial and estate planning purposes. A copy of the Form 45-102F1 – Notice of Intention to Distribution Securities under Section 2.8 of National Instrument 45-102 – Resale of Securities filed by the Selling Shareholder is available under the Company's profile on the System for Electronic Document Analysis and Retrieval + ("SEDAR+") at There is no assurance as to the timing of the proposed transactions thereunder nor whether any such transactions will occur. Required Early Warning Disclosure This additional disclosure is being provided pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which also requires a report to be filed by GR BCM2 #2 Acquisition Limited Partnership (the "Partnership") with the regulatory authorities in each jurisdiction in which the Company is a reporting issuer containing information with respect to the conversion of MVS to SVS in accordance with their terms (the "Conversion") to be completed in connection with the Sale (the "Early Warning Report"). Prior to the Conversion, Mr. Rosenberg, directly or indirectly, through entities owned and/or controlled, directly or indirectly by him, including the Partnership (the "Rosenberg Group"), held 8,704,535 MVS, representing 100% of the issued and outstanding MVS or 31.5% of the votes attached to all of the Company's issued and outstanding Shares, and 93,774 SVS, representing 0.05% of the issued and outstanding SVS or 0.03% of the votes attached to all of the Company's issued and outstanding Shares. In addition, Mr. Rosenberg held 168,582 restricted share units ("RSUs"), 225,629 performance share units ("PSUs") and 2,750,000 options ("Options"), each exercisable or settled for SVS. Following the Conversion, the Rosenberg Group held 8,254,535 MVS, representing 100% of the issued and outstanding MVS or 30.3% of the votes attached to all of the Company's issued and outstanding Shares, and 543,774 SVS, representing 0.29% of the issued and outstanding SVS or 0.20% of the votes attached to all of the Company's issued and outstanding Shares. Mr. Rosenberg intends to sell, directly or indirectly through the Partnership, up to 477,700 SVS pursuant to the Sale. In addition, Mr. Rosenberg continues to hold 168,582 RSUs, 225,629 PSUs and 2,750,000 Options, each exercisable or settled for SVS. Each MVS represents ten votes on all matters upon which holders of shares in the capital of the Company are entitled to vote and is convertible into one SVS at any time at the sole option of the holder. In addition to the Sale, the Rosenberg Group may, depending on market conditions, acquire additional SVS or dispose of MVS or SVS in the future whether in transactions over the open market or through privately negotiated arrangements or otherwise, subject to a number of factors, including general market conditions and investment diversification. The Company's head office is located at 181 Bay Street, Suite 2600, Toronto, Ontario, M5J 2T3. A copy of the Early Warning Report will be filed under the Company's profile on SEDAR+. The head office of the Selling Shareholder is 181 Bay Street, Suite 2600 Toronto, Ontario M5J 2T3.
